Laurus Labs to acquire additional stake of 7.24% in ImmunoACT

31 May 2023 Evaluate

Laurus Labs has signed definitive agreements to acquire additional stake of 7.24% in Immunoadoptive Cell Therapy (lmmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs 80 crore. 

Post the completion of the deal, Laurus Labs’ stake in ImmunoACT will increase to 33.86% (on fully diluted basis). This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19 along with the further expansion of the multi-location GMP facilities for manufacturing Chimeric Antigen Receptor T cells (CAR-T cells) treatment to support the growing need for scalable manufacturing. 

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.


Laurus Labs Share Price

1002.65 -12.25 (-1.21%)
15-Dec-2025 14:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1792.50
Dr. Reddys Lab 1280.10
Cipla 1504.95
Zydus Lifesciences 922.20
Lupin 2088.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×